Condition: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).
This description comes directly from the study's public registry record.
Sa Xiao, PHD · +8615013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Institute of Hematology, the First Hospital of Harbin | Haerbin, Heilongjiang, China | Not Yet Recruiting |
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Not Yet Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shangdong, China | Not Yet Recruiting |
| Shanghai Tongji Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| West China Hospital，Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05924750